Recombinant Human SMYD2 fused with GST tag at N-terminal was expressed in E. coli.
SMYD2 is a lysine mono-methyltransferase that has been shown to have activity on histone H3, p53 (Lys370), pRB (Lys380) and HSP90 (Lys616). The SMYD2 locus is amplified in lung carcinoma, serous ovarian carcinoma, and pancreatic ductal adenocarcinoma. SMYD2 expression is linked to a variety of cancers. Elevated levels of SMYD2 in esophageal squamous cell carcinoma patients are correlated with lower rates of survival.
In 100mM Tris pH 8.0, 10 mM glutathione and 10% glycerol.
Recombinant SMYD2, human is useful for histone H3 methylation experiments, enzyme kinetics and inhibitor screening. Use of 1-3 µg SMYD2 per reaction with recombinant histone H3 as a substrate is recommended.
Stable for six months at -80 centigrade from date of receipt. For best results, aliquot and avoid multiple freeze/thaws.